Access to COVID-19 Vaccines in High-, Middle-, and Low-Income Countries Hosting Clinical Trials
Reshma Ramachandran, Joseph S. Ross, Jennifer Miller
Abstract
avoid exploitation. These wealth-based access inequities among countries hosting trials parallel general disparities in COVID-19 vaccine access, as high-income countries have successfully procured and administered doses ahead of low-and middle-income countries. udy limitations include inability to determine the number of enrolled trial participants per country, which was not systematically reported, and the impact of manufacturing errors and safety concerns on dosage delivery, particularly affecting AstraZeneca and Janssen. Further, we focused on vaccination rates with vaccines tested in clinical trials hosted by each country, not overall vaccination rates with any authorized COVID-19 vaccine.